# A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

> **NCT07147257** · PHASE1 · COMPLETED · sponsor: **Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.** · enrollment: 238 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** CHS-1420
- **BIOLOGICAL:** HUMIRA®

## Key facts

- **NCT ID:** NCT07147257
- **Lead sponsor:** Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-12
- **Primary completion:** 2025-05-06
- **Final completion:** 2025-05-29
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147257, "A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07147257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*